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PREVALENCE OF OSTEOPENIA AND OSTEOPOROSIS AT THE
TIME OF DIAGNOSIS IN A SERIES OF ADULT CELIAC PATIENTS
P. Usai Satta∗ , F. Oppia, F. Cabras
Azienda Ospedaliera G. Brotzu, Cagliari, Italy
Background and aim: A low bone mass is a well-recognized manifestation
of celiac disease (CD). It can determine osteopenia or osteoporosis, and rarely
pathological fractures. A bone damage can be present even in the absence of
classical abdominal symptoms and also as only sign of disease. In literature,
the prevalence of osteoporosis in CD is about 35%, but these data generally
do not refer to the time of diagnosis, but to the follow-up.
We have evaluated the prevalence of osteopenia and osteoporosis at diagnosis,
in a series of adult celiac patients divided in different age groups.
Material and methods: As a ﬁrst step we have excluded celiac patients diag-
nosed at paediatric age and those with presumed secondary causes of low bone
mass, such as renal failure, cirrhosis, adrenal diseases, Down’s syndrome, mul-
tiple sclerosis, neoplasms etc. Then we have evaluated 219 consecutive adult
celiac patients (18–72 age ranged; F 186, 85%). Bone mineral density (BMD)
was assessed by dual-energy x-ray absorptiometry in lumbar spine and femoral
neck. A T-score of <–1 was considered as osteopenic and T-score <–2.5 at
any of these sites was considered osteoporosis. Patients have been divided in
three age class (15–30, 31–50 and >50 yrs) to compare T-score results.
Results: At diagnosis of CD, 32% of celiacs were osteopenic and 19% osteo-
porotic. A low bone mass was present in 38% of 15–30 group, 50% of 31–50
yrs and 73% of >50 yrs (>50 yrs vs other groups, p<0.02). No patient was
osteoporotic in 18–30 age class. Osteoporosis was more frequent in women in
post-menopause than in pre-menopause (58% vs 13%, p<0.0001), regardless
to Marsh grade. No signiﬁcant differences were found among age groups with
respect to osteopenia. Finally 50% of males (all >50 years) were osteoporic
and 19% osteopenic at diagnosis of CD.
Conclusions: Our study conﬁrms that women in post-menopause have a
higher bone damage, at diagnosis of CD. Our data suggest to perform a bone
densitometry at diagnosis of CD in males >30 years old and in females of any
age, especially in post-menopause condition where also other mechanisms can
be involved. The screening of osteopenia/osteoporosis is pivotal in CD where
a low bone mass may be the only sign of undiagnosed disease. The usefulness
of screening osteoporotic patients systematically for CD is instead still an
open question.
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MUCOSAL DUODENAL TISSUE FROM GLUTEN-SENSITIVE
PATIENTS DO NOT HAVE INCREASED EXPRESSION OF IgA
B-CELL SWITCH MARKERS
A. Sapone∗ ,2, A. Cirillo 2 , A. Picardi 2 , M. Hritzo1, P. Castillo 1 , R. Cariello 2 ,
G. Riegler 2, K. Lammers 1, A. Fasano1, L. De Magistris 2
1Mucosal Biology Research, University of Maryland, Baltimore, United
States; 2SUN, Napoli, Italy
Background and aim: Gluten-sensitive individuals (GS) cannot tolerate
gluten and may develop gastrointestinal symptoms similar to those in celiac
disease (CD), but the overall clinical picture is generally less severe and is
not accompanied by the presence of tissue transglutaminase autoantibodies
(tTG) or autoimmune co-morbidities. We have previously shown that higher
numbers of recently activated B cells and IgA-isotype switched plasma cells
could be detected in the active CD intestinal mucosa, suggesting in loco
gliadin-induced B-cell activation and switch into IgA-producing plasma cells.
Aim was to investigate the involvement of mucosal B cell activation in
the Gluten Sensitive patients by measuring of Activation Induced Cytidine
Deaminase (AICD) gene expression, and I-alpha germline & C-alpha mature
transcripts that are signal of B cell differentiation.
Material and methods: B-cell activation and differentiation into IgA-
secreting plasma cells were assessed in the intestinal mucosa from 10
HC, 16 active CD- and 13 GS-patients by measuring of (AICD) gene expres-
sion and of Iα germline and Cα mature transcripts by real-time RT-PCR of
bioptic cDNA.
Results: Compared to HC, CD showed signiﬁcantly higher expression of
mucosal B-cell activation marker AICD (p=0.004), and mucosal IgA isotype
switch markers Iα (p=0.021) and Cα (p=0.003). In contrast, GS patients had
mucosal B-cell activation and IgA isotype switch markers similar to values
detected in HC.
Conclusions: These ﬁndings support and extend the idea that, the two gluten-
associated disorders, CD and GS, are different clinical entities where GS is a
condition prevalently associated with gluten-induced activation of the innate,
rather than adaptive, immune response.
P.06.1
INTRA-DUODENAL RELEASE OF A BITTER COMPOUND
DECREASES CALORIC INTAKE IN HEALTHY VOLUNTEERS
P. Andreozzi, F.P. Zito, M. Della Coletta, M. Pesce, R. D’Aniello, G. Sarnelli,
R. Cuomo ∗
Dipartimento di Medicina Clinica e Sperimantale “Università Federico II”,
Napoli, Italy
Background and aim: α-gustducin and bitter taste receptors (T2R) are
expressed both in the oral cavity and in the gastrointestinal (GI) tract. Exper-
imental data showed that bitter tastants induce the release of gut hormones
from enteroendocrine cells in the gut, suggesting a possible role of bitter taste
receptors in the control of food intake and GI functions. We aimed to test the
effects of a bitter taste receptor agonist on food intake and GI feelings.
Material and methods: We enrolled 19 healthy subjects (9 males, age 27±7,
BMI 24±6) in a double-blind placebo controlled study. Each subject randomly
received an acid-resistant capsule containing placebo or 18 mg of quinine
HCl. 60 minutes after capsule administration, the subjects underwent to an ad
libitum test, until the maximum satiation. Meal test was composed by white
bread, cheese and meat cream (89 kcal/portion: 50% carbohydrate, 31% fat,
19% protein). Caloric intake, meal duration and satiation levels, scored on a
Visual Analogue Scale (VAS) were calculated at the end of the meal test. A
questionnaire assessing GI sensations (bloating, fullness, nausea, epigastric
discomfort and hunger) was administered before and at the end of the test.
Data (mean ± SD) were compared by using paired t test.
Results: No oral bitter sensation or side effects was observed both with
quinine HCland placebo. No signiﬁcant differences in terms of GI sensations
and hunger feelings were observed between the two sessions of the study. The
amount of calories ingested was signiﬁcantly lower when subjects received
quinine HCl than placebo (564±262 vs 667±278 kcal; p=0.02). Conversely,
quinine HCl did not affect the meal duration (14.4±4.2 vs 16.6±4.6 min;
p=NS) and the satiationintensity (82 vs 82 mm; p=NS).
Conclusions: The intra-duodenal release of a bitter compound signiﬁcantly de-
creases caloric intake in an ad libitum test meal without affecting GI sensations
and hunger feeling. As the bitter compound does not inﬂuence meal duration,
we hypothesize that quinine HCl decreases the caloric intake by affecting the
rate of meal portions consumption. Evaluation of gut hormones kinetics and
studies with other bitter taste receptor agonist are needed to establish the role
of gastrointestinal bitter taste receptor in the control of food intake.
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EFFECT OF BARIATRIC SURGERY ON SERUM LEVELS OF
GASTROINTESTINAL HORMONES IN OBESE NAFLD PATIENTS
A. Federico ∗ , M.D. Iadevaia, A.L. Mozzillo, V. Amoroso, S. Tolone,
R. Meucci, G. Rossetti, L. Docimo, C. Loguercio
Unit of Hepatogastroenterology and Unit of Bariatric Surgery, Centro
Interuniversitario di Ricerca su Alimenti, Nutrizione e Apparato Digerente
(CIRANAD), Dipartimento Medico-Chirurgico di Internistica Clinica e
Sperimentale “F. Magrassi e A. Lanzara”, Seconda Università degli Studi di
Napoli, Naples, Italy
Background and aim: The gut releases a number of humoural peptides that
signal to the brain to control food intake and to control energy homeostasis,
such as peptide YY (PYY), glucagon-like peptide (GLP)-1, GLP-2, ghre-
lin (GHR), orexin (ORE) and cholecystokinin (CCK). Over the last years,
